Status:
COMPLETED
Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
Brief Summary
Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma
Eligibility Criteria
Inclusion
- Asthmatic patients treated for this disease with Symbicort Turbuhaler
- Patients monitored for asthma by the doctor for at least 12 months
- Patients seen in outpatient care at the baseline visit
- Patients agreeing to participate in the study
Exclusion
- Patients with any chronic lower respiratory disease other than asthma
- Patients receiving anti-IgE agents in the last 4 months
- Patients receiving desensitisation treatment outside of the maintenance phase
- Patients deemed to be unable to respond to the study for linguistic or cognitive reasons
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
579 Patients enrolled
Trial Details
Trial ID
NCT00812357
Start Date
April 1 2009
End Date
August 1 2011
Last Update
December 29 2011
Active Locations (168)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Dessenheim, Alsace, France
2
Research Site
Duppigheim, Alsace, France
3
Research Site
Haguenau, Alsace, France
4
Research Site
Obernai, Alsace, France